%22%2F%3E%0A%3Cdefs%3E%0A%3CradialGradient%20id%3D%22paint0_radial_53404_20784%22%20cx%3D%220%22%20cy%3D%220%22%20r%3D%221%22%20gradientUnits%3D%22userSpaceOnUse%22%20gradientTransform%3D%22translate(11.6786%2037.1765)%20scale(40.1126%2040.1123)%22%3E%0A%3Cstop%20stop-color%3D%22%23B4C9EA%22%2F%3E%0A%3Cstop%20offset%3D%221%22%20stop-color%3D%22%23426BBA%22%2F%3E%0A%3C%2FradialGradient%3E%0A%3C%2Fdefs%3E%0A%3C%2Fsvg%3E%0A)
Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
Study Identifier:
417-201-00060
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
EU CT ID:
N/A
Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Autoimmune/Kidney Disease
Study Drug
- Drug: Sibeprenlimab
Date
Nov 2024 - Apr 2029
Phase 1/2
Phase 2/3
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 16+ years
Requirements Information
Protocol Summary
This is a phase 2b open-label trial to characterize histopathological biomarkers of disease in immunoglobulin A nephropathy (IgAN) and demonstrate potential changes in response to sibeprenlimab.
Study Locations
Location
Status
Location
Clinical Research Site 330
Denver, Colorado, United States, 80230
Status
Recruiting
Location
Clinical Research Site 369
Boston, Massachusetts, United States, 21144
Status
Recruiting
Location
Clinical Research Site 374
Dakota Dunes, South Dakota, United States, 57409
Status
Recruiting
Location
Clinical Research Site 324
Houston, Texas, United States, 77054
Status
Recruiting
Location
Clinical Research Site 305
Scarborough, Ontario, Canada, M1H 3G4
Status
Recruiting